雍禾醫療(02279.HK):部分行使超額配股權、穩定價格行動及穩定價格期結束
格隆匯1月5日丨雍禾醫療(02279.HK)公吿,聯席全球協調人(代表國際包銷商)已於2022年1月5日部分行使招股章程所述的超額配股權,涉及合共712.45萬股股份,佔任何超額配股權獲行使前根據全球發售初步可供認購的發售股份總數約7.5%。
超額配發股份將由本公司按每股發售股份15.80港元(不包括1%經紀佣金、0.0027%證監會交易徵費、0.005%聯交所交易費及0.00015%財務彙報局交易徵費)(即全球發售的每股發售股份發售價)配發及發行。超額配發股份將用於促使向ZY Investment Capital Ltd 部分歸還所借入1416.35萬股用於補足國際發售的超額分配的股份。
公司進一步宣佈,有關全球發售的穩定價格期於2022年1月5日(星期三)結束,即遞交香港公開發售申請截止日期起計第30天。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.